The healthcare sector is heterogeneous, with a wide dispersion in returns between the best- and worst-performing stocks.

DNA hydrogels are biocompatible drug delivery systems for targeted therapeutic interventions. Conventional DNA hydrogels, formed with many DNA nanostructure units, lead to increased preparation costs ...

We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...

The NIH says funding cuts would save it billions of dollars a year. D.C.-area industry and academic leaders say it would cripple R&D.

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Biogen Inc. has agreed to pay as much as $550 million to develop and sell a drug to treat a genetic seizure disorder, the latest effort by the biotech company to fill holes in its pipeline.Biogen will ...

Stoke Therapeutics Inc. (Nasdaq: STOK) has pulled in Biogen (Nasdaq: BIIB) to help it develop and commercialize a treatment ...

The biotech industry is on a stable growth path, owing to the integration of modern technologies and rapid drug discoveries.

Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...

Latigo Biotherapeutics, a non-opioid pain biotech looking to ride the waves created by Vertex Pharmaceuticals' pain drug ...

Jill Collins, CEO, Chief Strategy Officer, Audacity Health.

Compugen's innovative approach targets under-explored immune pathways like PVRIG and IL-18 binding protein. Read why I'm ...